This carcinogen generates fibrosarcomas when injected intramuscularly in mice, and tumors carry frequent oncogenic mutations in K-Ras or N-Ras[28], [39]–[41], together with a high incidence of p53 inactivation by deletion or point mutation [41], [42]. The gene discussed is KRAS; the disease is fibrosarcoma.